Kisspeptin-10 and PT-141 Together: What Is Known
Kisspeptin-10 and PT-141 taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Interaction notes
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
We have no sourced data on taking these two together. Ask the prescriber who manages both.
Each component
Side by side
Showing 11 of 14 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Kisspeptin-10 | PT-141 |
|---|---|---|
| Class | GnRH stimulator | Melanocortin agonist |
| Also called | kiss | Vyleesi, PT141 |
| Category | Sexual & hormonal health | Sexual & hormonal health |
| FDA status | Not FDA approved · research chemical | FDA approved for HSDD (Vyleesi) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.1)Kisspeptin and its agonist analogues are named in S2.2.1 (testosterone-stimulating peptides in males). | Not on the WADA Prohibited ListPT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | mean elimination half-life 1.3-2.2 hourssubcutaneous (analog MVT-602) · Fertility and sterility 2024, PMID 37925096 | approximately 2.7 hours (range 1.9-4.0 h)subcutaneous · FDA label (Vyleesi) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: European journal of endocrinology 2026, PMID 42549827 | Human RCT evidence, 4 of 4Strongest: Journal of women's health 2022, PMID 35230162 |
| Human studies we summarised | 13 human (10 randomized or controlled) of 16 summarised | 12 human (12 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg | 10 mg |
| US searches per month | 22,200 · +371% searches | 67,600 · +123% searches |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Related tools
Kisspeptin-10 vs PT-141
Choosing between the two rather than combining them? The comparison lines them up field by field.
What people search
- kisspeptin and pt 14140/mo
- pt 141 and kisspeptin20/mo
- pt 141 kisspeptin10/mo
- pt 141 and kisspeptin together10/mo
- kisspeptin pt 14110/mo
- kisspeptin and pt 141 together10/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3[Not Available].Biomedical chromatography : BMC · 2024PMID 38978171Accessed 2 Oct 2026
- 4Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes.Drug testing and analysis · 2026PMID 42057309Accessed 2 Oct 2026
- 5Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 6Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 7Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 8These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 9Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 11Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 12PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] OR Vyleesi[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.